Free Trial
→ Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps (From Weiss Ratings) (Ad) Buy RVMD Stock  Free RVMD Stock Alerts

Revolution Medicines (RVMD) Financials

Revolution Medicines logo
$39.79 -0.93 (-2.28%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$38.75 -1.04 (-2.61%)
As of 07:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Revolution Medicines

Annual Income Statements for Revolution Medicines

This table shows Revolution Medicines' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -49 -62 -110 -187 -249 -436 -600
Consolidated Net Income / (Loss)		 -42 -48 -108 -187 -249 -436 -600
Net Income / (Loss) Continuing Operations		 -42 -48 -108 -187 -249 -436 -600
Total Pre-Tax Income 		-42 -52 -109 -187 -249 -440 -601
Total Operating Income		 -40 -54 -111 -188 -258 -487 -690
Total Gross Profit		 20 50 43 29 35 12 0.00
Total Revenue		 20 50 43 29 35 12 0.00
Operating Revenue		 20 50 43 29 35 12 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 60 104 154 217 294 499 690
Selling, General & Admin Expense		 9.41 12 21 30 41 76 97
Research & Development Expense		 51 92 132 187 253 423 592
Total Other Income / (Expense), net		 -1.46 2.08 2.17 0.92 9.15 47 89
Interest & Investment Income		 0.78 2.19 2.24 0.93 9.15 47 87
Other Income / (Expense), net		 -2.12 - - -0.01 0.00 -0.19 -2.53
Income Tax Expense		 0.00 -4.37 -0.37 0.00 -0.42 -3.52 -0.75
Basic Earnings per Share		 ($21.24) ($22.33) ($2.01) ($2.57) ($3.08) ($3.86) ($3.58)
Weighted Average Basic Shares Outstanding		 2.30M 2.77M 54.87M 72.81M 80.63M 113.15M 167.74M
Diluted Earnings per Share		 ($21.24) ($22.33) ($2.01) ($2.57) ($3.08) ($3.86) ($3.58)
Weighted Average Diluted Shares Outstanding		 2.30M 2.77M 54.87M 72.81M 80.63M 113.15M 167.74M
Weighted Average Basic & Diluted Shares Outstanding		 2.30M 2.77M 54.87M 72.81M 90.49M 164.69M 185.91M

Quarterly Income Statements for Revolution Medicines

This table shows Revolution Medicines' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -73 -53 -68 -98 -108 -162 -116 -133 -156 -195
Consolidated Net Income / (Loss)		 -73 -53 -68 -98 -108 -162 -116 -133 -156 -195
Net Income / (Loss) Continuing Operations		 -73 -53 -68 -98 -108 -162 -116 -133 -156 -195
Total Pre-Tax Income 		-74 -53 -68 -98 -112 -161 -116 -133 -156 -195
Total Operating Income		 -77 -58 -75 -109 -123 -180 -141 -157 -176 -216
Total Operating Expenses		 80 71 82 113 123 181 141 157 176 216
Selling, General & Admin Expense		 10 9.74 13 15 16 32 23 22 24 29
Research & Development Expense		 69 62 69 98 108 148 118 135 152 188
Total Other Income / (Expense), net		 2.91 4.51 7.06 10 11 19 25 23 19 21
Interest & Investment Income		 2.91 4.51 7.06 10 11 19 24 21 20 21
Other Income / (Expense), net		 - - 0.00 0.00 0.00 -0.19 1.10 1.92 0.28 -5.83
Income Tax Expense		 -0.30 -0.12 0.00 0.00 -3.87 0.34 0.00 0.00 0.00 -0.75
Basic Earnings per Share		 ($0.87) ($0.57) ($0.72) ($0.92) ($0.99) ($1.23) ($0.70) ($0.81) ($0.94) ($1.13)
Weighted Average Basic Shares Outstanding		 84.69M 80.63M 94.83M 106.88M 109.23M 113.15M 164.73M 165.14M 166.84M 167.74M
Diluted Earnings per Share		 ($0.87) ($0.57) ($0.72) ($0.92) ($0.99) ($1.23) ($0.70) ($0.81) ($0.94) ($1.13)
Weighted Average Diluted Shares Outstanding		 84.69M 80.63M 94.83M 106.88M 109.23M 113.15M 164.73M 165.14M 166.84M 167.74M
Weighted Average Basic & Diluted Shares Outstanding		 88.79M 90.49M 109.17M - 109.56M 164.69M 164.99M 167.04M 168.22M 185.91M

Annual Cash Flow Statements for Revolution Medicines

This table details how cash moves in and out of Revolution Medicines' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 61 -53 88 4.88 53 536 -152
Net Cash From Operating Activities		 1.21 -50 -100 -147 -224 -351 -557
Net Cash From Continuing Operating Activities		 1.21 -50 -100 -147 -224 -356 -557
Net Income / (Loss) Continuing Operations		 -42 -48 -108 -187 -249 -436 -600
Consolidated Net Income / (Loss)		 -42 -48 -108 -187 -249 -436 -600
Depreciation Expense		 1.57 2.27 2.61 3.08 3.97 - 6.56
Amortization Expense		 0.20 0.62 4.90 7.26 2.61 -18 -39
Non-Cash Adjustments To Reconcile Net Income		 3.18 3.98 8.89 21 31 62 75
Changes in Operating Assets and Liabilities, net		 38 -8.83 -8.30 8.72 -13 37 0.65
Net Cash From Investing Activities		 -1.34 -102 -234 -142 -24 -343 -554
Net Cash From Continuing Investing Activities		 -1.34 -102 -234 -142 -24 -343 -554
Purchase of Property, Plant & Equipment		 -1.50 -2.59 -2.93 -6.53 -11 -7.73 -10
Purchase of Investments		 0.00 -172 -544 -671 -613 -1,059 -2,137
Sale and/or Maturity of Investments		 0.00 67 313 536 599 724 1,593
Net Cash From Financing Activities		 61 99 423 294 301 1,229 959
Net Cash From Continuing Financing Activities		 61 99 423 294 301 1,229 959
Issuance of Common Equity		 0.42 0.28 423 295 301 392 959
Other Financing Activities, net		 0.13 -1.65 0.00 -0.42 0.04 837 0.28

Quarterly Cash Flow Statements for Revolution Medicines

This table details how cash moves in and out of Revolution Medicines' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 73 -18 266 -46 -22 338 -408 -13 -75 343
Net Cash From Operating Activities		 -52 -62 -62 -67 -100 -121 -161 -128 -130 -138
Net Cash From Continuing Operating Activities		 -52 -62 -62 -67 -100 -126 -161 -128 -130 -138
Net Income / (Loss) Continuing Operations		 -73 -57 -68 -98 -108 -162 -116 -133 -156 -195
Consolidated Net Income / (Loss)		 -73 -57 -68 -98 -108 -162 -116 -133 -156 -195
Depreciation Expense		 0.99 1.15 1.21 1.22 1.27 - 1.54 1.64 1.64 1.74
Amortization Expense		 0.28 -1.14 -2.25 -4.30 -4.27 -7.12 -14 -9.75 -8.36 -7.17
Non-Cash Adjustments To Reconcile Net Income		 8.14 8.32 9.70 13 14 26 15 18 22 19
Changes in Operating Assets and Liabilities, net		 12 -14 -2.95 21 -2.73 21 -47 -4.74 10 42
Net Cash From Investing Activities		 -123 -7.10 4.00 -44 77 -380 -248 108 -21 -393
Net Cash From Continuing Investing Activities		 -123 -7.10 4.00 -44 77 -380 -248 108 -21 -393
Purchase of Property, Plant & Equipment		 -3.53 -2.88 -1.76 -1.12 -2.54 -2.32 -3.17 -2.40 -3.52 -1.22
Purchase of Investments		 -213 -160 -193 -176 -170 -520 -702 -375 -365 -695
Sale and/or Maturity of Investments		 93 156 199 134 250 142 457 485 347 304
Net Cash From Financing Activities		 248 51 324 65 1.01 839 0.81 7.50 77 874
Net Cash From Continuing Financing Activities		 248 51 324 65 1.01 839 0.81 7.50 77 874
Issuance of Common Equity		 248 51 324 65 1.01 2.55 0.81 7.50 77 874

Annual Balance Sheets for Revolution Medicines

This table presents Revolution Medicines' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 221 567 738 812 2,062 2,558
Total Current Assets		 134 454 590 660 1,879 2,328
Cash & Equivalents		 17 104 108 161 696 543
Short-Term Investments		 106 336 469 484 1,157 1,746
Accounts Receivable		 8.74 6.39 5.93 4.67 1.25 0.00
Prepaid Expenses		 2.49 6.99 6.79 11 25 38
Plant, Property, & Equipment, net		 7.15 8.90 12 19 23 24
Total Noncurrent Assets		 79 104 137 133 160 206
Goodwill		 15 15 15 15 15 15
Intangible Assets		 62 61 60 59 58 57
Other Noncurrent Operating Assets		 2.78 29 62 60 87 135
Total Liabilities & Shareholders' Equity		 221 567 738 812 2,062 2,558
Total Liabilities		 68 93 135 127 236 293
Total Current Liabilities		 43 47 60 62 144 164
Accounts Payable		 11 13 14 21 62 54
Accrued Expenses		 15 19 28 29 75 97
Other Current Liabilities		 0.00 3.67 6.21 6.77 7.37 13
Total Noncurrent Liabilities		 25 46 75 65 92 129
Noncurrent Deferred & Payable Income Tax Liabilities		 7.82 7.44 7.44 7.03 3.12 2.35
Other Noncurrent Operating Liabilities		 0.66 30 61 58 89 127
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -153 475 603 685 1,826 2,265
Total Preferred & Common Equity		 -153 475 603 685 1,826 2,265
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -153 475 603 685 1,826 2,265
Common Stock		 4.74 740 1,056 1,388 2,963 4,002
Retained Earnings		 -157 -266 -453 -701 -1,138 -1,738
Accumulated Other Comprehensive Income / (Loss)		 0.07 0.12 -0.38 -1.78 0.54 1.32

Quarterly Balance Sheets for Revolution Medicines

This table presents Revolution Medicines' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 826 1,074 984 1,908 1,808 1,763
Total Current Assets		 675 922 824 1,729 1,625 1,579
Cash & Equivalents		 179 380 358 288 276 201
Short-Term Investments		 476 529 455 1,415 1,315 1,348
Accounts Receivable		 4.94 2.51 0.31 0.00 0.00 0.00
Prepaid Expenses		 15 10 11 26 34 30
Plant, Property, & Equipment, net		 18 20 20 24 25 25
Total Noncurrent Assets		 133 132 139 155 158 159
Goodwill		 15 15 15 15 15 15
Intangible Assets		 59 58 58 57 57 57
Other Noncurrent Operating Assets		 59 59 67 83 87 88
Total Liabilities & Shareholders' Equity		 826 1,074 984 1,908 1,808 1,763
Total Liabilities		 144 143 147 183 190 197
Total Current Liabilities		 73 78 86 94 105 111
Accounts Payable		 24 30 30 32 29 24
Accrued Expenses		 32 43 50 53 68 78
Other Current Liabilities		 7.02 5.72 5.76 8.17 8.33 8.40
Total Noncurrent Liabilities		 71 65 61 89 84 86
Noncurrent Deferred & Payable Income Tax Liabilities		 7.15 7.03 3.16 3.12 3.12 3.12
Other Noncurrent Operating Liabilities		 59 58 58 86 81 83
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 681 931 837 1,725 1,619 1,566
Total Preferred & Common Equity		 681 931 837 1,725 1,619 1,566
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 681 931 837 1,725 1,619 1,566
Common Stock		 1,329 1,800 1,815 2,980 3,008 3,106
Retained Earnings		 -645 -868 -976 -1,254 -1,387 -1,543
Accumulated Other Comprehensive Income / (Loss)		 -2.42 -1.25 -0.87 -1.20 -1.86 3.81

Annual Metrics and Ratios for Revolution Medicines

This table displays calculated financial ratios and metrics derived from Revolution Medicines' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 148.16% -14.10% -31.62% 20.38% -67.27% -100.00%
EBITDA Growth		 0.00% -25.91% -101.42% -72.19% -41.66% -100.76% -43.44%
EBIT Growth		 0.00% -27.49% -104.54% -69.85% -37.37% -88.70% -42.00%
NOPAT Growth		 0.00% -34.20% -104.54% -69.84% -37.38% -88.63% -41.53%
Net Income Growth		 0.00% -14.06% -126.92% -72.98% -32.93% -75.46% -37.52%
EPS Growth		 0.00% -5.13% 91.00% -27.86% -19.84% -25.32% 7.25%
Operating Cash Flow Growth		 0.00% -4,190.35% -101.68% -47.09% -52.47% -56.23% -59.01%
Free Cash Flow Firm Growth		 0.00% 0.00% -20.67% -50.88% -58.73% -40.15% -77.11%
Invested Capital Growth		 0.00% 0.00% 13.96% -24.82% 57.74% -166.50% 9.96%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 2.47% 13.95% -52.98% -100.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -11.40% -3.11% -35.88% -6.09%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -11.14% -1.84% -33.61% -6.46%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -11.13% -1.84% -33.56% -5.56%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -10.95% -0.10% -33.14% -5.83%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -14.73% 4.64% -20.63% 2.72%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -15.44% -10.70% -11.16% -20.14% -3.28%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -12.12% -8.23% -7.90%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -13.66% 52.41% -210.30% -243.23%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 -201.77% -102.37% -240.06% -604.55% -711.42% -4,363.65% 0.00%
Operating Margin		 -200.00% -108.15% -257.54% -639.70% -730.01% -4,207.12% 0.00%
EBIT Margin		 -210.51% -108.15% -257.54% -639.74% -730.01% -4,208.75% 0.00%
Profit (Net Income) Margin		 -207.24% -95.25% -251.63% -636.58% -702.95% -3,768.28% 0.00%
Tax Burden Percent		 100.00% 91.60% 99.66% 100.00% 99.83% 99.20% 99.87%
Interest Burden Percent		 98.44% 96.15% 98.04% 99.51% 96.46% 90.26% 86.82%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -254.45% -243.24% -442.75% -549.87% -5,058.28% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -238.52% -232.36% -431.85% -538.76% -5,050.65% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 191.96% 208.76% 408.02% 511.25% 5,023.53% 0.00%
Return on Equity (ROE)		 0.00% -62.50% -34.49% -34.74% -38.63% -34.75% -29.33%
Cash Return on Invested Capital (CROIC)		 0.00% -454.45% -256.30% -414.42% -594.68% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -24.54% -28.10% -28.81% -33.33% -33.92% 0.00%
Return on Assets (ROA)		 0.00% -21.61% -27.45% -28.66% -32.09% -30.37% 0.00%
Return on Common Equity (ROCE)		 0.00% 62.51% -17.71% -34.74% -38.63% -34.75% -29.33%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 31.24% -22.79% -31.05% -36.30% -23.89% -26.49%
Net Operating Profit after Tax (NOPAT)		 -28 -38 -77 -132 -181 -341 -483
NOPAT Margin		 -140.00% -75.71% -180.28% -447.79% -511.01% -2,944.99% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -15.93% -10.89% -10.90% -11.11% -7.63% -5.67%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -26.39% -18.67% -21.31%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 46.67% 24.79% 49.85% 103.61% 114.71% 653.03% 0.00%
R&D to Revenue		 253.33% 183.36% 307.68% 636.09% 715.30% 3,654.09% 0.00%
Operating Expenses to Revenue		 300.00% 208.15% 357.54% 739.70% 830.01% 4,307.12% 0.00%
Earnings before Interest and Taxes (EBIT)		 -42 -54 -111 -188 -258 -487 -692
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -41 -51 -103 -178 -252 -505 -725
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 5.54 3.08 3.09 1.72 3.25
Price to Tangible Book Value (P/TBV)		 0.00 0.00 6.58 3.51 3.46 1.79 3.35
Price to Revenue (P/Rev)		 7.44 3.00 61.14 63.11 59.78 271.36 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 11.16 64.45 50.08 36.53 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 6.64 50.89 43.47 41.55 111.34 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.80 -0.90 -0.94 -0.95 -0.99 -1.01
Leverage Ratio		 0.00 1.45 1.26 1.21 1.20 1.14 1.13
Compound Leverage Factor		 0.00 1.39 1.23 1.21 1.16 1.03 0.98
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 200.03% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -100.03% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.24 16.64 7.42 8.68 7.47 14.23
Noncontrolling Interest Sharing Ratio		 0.00% 200.03% 48.65% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 3.11 9.63 9.77 10.65 13.06 14.20
Quick Ratio		 0.00 3.05 9.48 9.66 10.48 12.89 13.97
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -68 -82 -123 -196 -274 -485
Operating Cash Flow to CapEx		 80.92% -2,073.38% -3,411.66% -2,254.60% -2,074.71% -4,535.80% -5,407.80%
Free Cash Flow to Firm to Interest Expense		 0.00 -638.31 -1,149.94 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 10.46 -468.08 -1,409.35 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -2.47 -490.65 -1,450.66 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.23 0.11 0.05 0.05 0.01 0.00
Accounts Receivable Turnover		 0.00 5.73 5.68 4.77 6.67 3.91 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 7.00 5.36 2.87 2.34 0.56 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 63.73 64.24 76.51 54.69 93.41 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 63.73 64.24 76.51 54.69 93.41 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 30 34 26 40 -27 -24
Invested Capital Turnover		 0.00 3.36 1.35 0.99 1.08 1.72 0.00
Increase / (Decrease) in Invested Capital		 0.00 30 4.16 -8.42 15 -67 2.67
Enterprise Value (EV)		 0.00 332 2,187 1,278 1,470 1,289 5,069
Market Capitalization		 150 150 2,628 1,855 2,115 3,142 7,358
Book Value per Share		 $0.00 ($55.03) $7.15 $8.18 $7.72 $16.67 $13.47
Tangible Book Value per Share		 $0.00 ($82.66) $6.01 $7.17 $6.89 $16.01 $13.04
Total Capital		 0.00 153 475 603 685 1,826 2,265
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -123 -441 -577 -645 -1,853 -2,289
Capital Expenditures (CapEx)		 1.50 2.39 2.93 6.53 11 7.73 10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -32 -34 -48 -47 -118 -126
Debt-free Net Working Capital (DFNWC)		 0.00 91 407 529 598 1,735 2,164
Net Working Capital (NWC)		 0.00 91 407 529 598 1,735 2,164
Net Nonoperating Expense (NNE)		 14 9.78 31 55 68 95 117
Net Nonoperating Obligations (NNO)		 0.00 -123 -441 -577 -645 -1,853 -2,289
Total Depreciation and Amortization (D&A)		 1.76 2.89 7.51 10 6.58 -18 -33
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -63.61% -78.62% -162.07% -132.11% -1,014.90% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 181.71% 946.76% 1,801.37% 1,690.79% 14,986.44% 0.00%
Net Working Capital to Revenue		 0.00% 181.71% 946.76% 1,801.37% 1,690.79% 14,986.44% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.01) ($2.57) ($3.08) ($3.86) ($3.58)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 73.38M 74.19M 80.63M 113.15M 167.74M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.01) ($2.57) ($3.08) ($3.86) ($3.58)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 73.38M 74.19M 80.63M 113.15M 167.74M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.01) ($2.57) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 54.87M 72.81M 90.49M 164.69M 185.91M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -38 -77 -132 -181 -341 -483
Normalized NOPAT Margin		 -140.00% -75.71% -180.28% -447.79% -511.01% -2,944.99% 0.00%
Pre Tax Income Margin		 -207.24% -103.99% -252.50% -636.58% -704.14% -3,798.71% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 -365.95 -510.57 -1,559.11 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -243.36 -357.40 -1,091.38 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -378.87 -533.14 -1,600.42 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -256.29 -379.97 -1,132.69 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Revolution Medicines

This table displays calculated financial ratios and metrics derived from Revolution Medicines' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 204.81% 45.79% -23.06% -58.05% -100.00% -94.62% -100.00% -100.00% 0.00% 0.00%
EBITDA Growth		 -48.98% -15.22% -28.82% -87.31% -67.75% -225.38% -99.79% -45.54% -44.28% -21.51%
EBIT Growth		 -43.96% -8.80% -21.05% -75.23% -61.04% -212.97% -85.96% -42.21% -42.34% -23.29%
NOPAT Growth		 -43.96% -8.80% -21.05% -75.23% -61.04% -212.64% -87.42% -43.98% -42.57% -20.18%
Net Income Growth		 -38.51% -0.49% -11.23% -60.56% -47.87% -205.18% -70.35% -35.54% -44.13% -20.45%
EPS Growth		 -20.83% 20.83% 12.20% -12.20% -13.79% -115.79% 2.78% 11.96% 5.05% 8.13%
Operating Cash Flow Growth		 -41.40% -57.36% -13.11% -20.47% -94.25% -95.12% -157.34% -90.95% -29.77% -14.70%
Free Cash Flow Firm Growth		 -81.19% -92.29% -20.17% 8.15% -66.83% -7.18% -137.75% -255.57% -37.36% -161.24%
Invested Capital Growth		 -10.64% 57.74% -33.79% 0.00% -8.12% -166.50% 2.72% 0.00% -30.66% 9.96%
Revenue Q/Q Growth		 -63.19% 310.97% -49.14% -45.48% -100.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -26.01% 23.52% -32.38% -46.82% -12.85% -48.35% 18.04% -6.95% -11.87% -24.94%
EBIT Q/Q Growth		 -23.26% 24.78% -30.55% -44.76% -13.28% -46.19% 22.35% -10.70% -13.39% -26.63%
NOPAT Q/Q Growth		 -23.26% 24.78% -30.55% -44.76% -13.28% -46.03% 21.74% -11.21% -12.17% -23.10%
Net Income Q/Q Growth		 -19.78% 27.82% -28.65% -44.35% -10.31% -48.97% 28.19% -14.85% -17.30% -24.49%
EPS Q/Q Growth		 -6.10% 34.48% -26.32% -27.78% -7.61% -24.24% 43.09% -15.71% -16.05% -20.21%
Operating Cash Flow Q/Q Growth		 7.14% -19.43% -0.98% -7.58% -49.73% -19.97% -33.18% 20.18% -1.76% -6.04%
Free Cash Flow Firm Q/Q Growth		 -19.54% -9.12% 24.19% 7.11% -117.11% 29.89% -68.16% -38.92% 16.13% -33.34%
Invested Capital Q/Q Growth		 -29.41% 52.41% -46.96% -100.00% 0.00% -210.30% 181.94% 28.30% -40.20% -243.23%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -2,242.58% -417.35% -1,086.41% -2,925.60% 0.00% -25,241.64% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -2,280.48% -417.40% -1,071.53% -2,845.11% 0.00% -24,256.47% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -2,280.48% -417.40% -1,071.53% -2,845.11% 0.00% -24,281.81% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -2,185.01% -383.79% -970.89% -2,570.55% 0.00% -21,770.49% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.60% 99.77% 100.00% 100.00% 96.56% 100.21% 100.00% 100.00% 100.00% 99.61%
Interest Burden Percent		 96.20% 92.16% 90.61% 90.35% 91.12% 89.47% 83.00% 86.11% 89.09% 87.93%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,771.53% -314.40% -931.63% 0.00% 0.00% -29,163.89% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,768.41% -312.33% -929.47% 0.00% 0.00% -29,161.04% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 1,693.42% 296.38% 895.86% 0.00% 0.00% 29,004.47% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -78.11% -18.02% -35.78% 0.00% 0.00% -159.42% 0.00% 0.00% 0.00% -29.33%
Cash Return on Invested Capital (CROIC)		 -623.34% -594.68% -668.28% 0.00% -999.41% 0.00% -1,791.43% -3,189.47% -2,189.54% 0.00%
Operating Return on Assets (OROA)		 -90.72% -19.06% -40.60% 0.00% 0.00% -195.70% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -86.93% -17.52% -36.79% 0.00% 0.00% -175.46% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -78.11% -18.02% -35.78% 0.00% 0.00% -159.42% 0.00% 0.00% 0.00% -29.33%
Return on Equity Simple (ROE_SIMPLE)		 -36.46% 0.00% -27.46% 0.00% -39.14% 0.00% -28.07% -32.07% -36.20% 0.00%
Net Operating Profit after Tax (NOPAT)		 -54 -40 -53 -76 -86 -126 -99 -110 -123 -151
NOPAT Margin		 -1,596.34% -292.18% -750.07% -1,991.58% 0.00% -16,979.53% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.13% -2.07% -2.17% 0.00% -3.02% -2.85% -1.33% -2.97% -2.82% -2.08%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.88% - - - -6.90% - - - -6.68%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 310.91% 70.65% 188.54% 382.85% 0.00% 4,345.55% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 2,069.58% 446.75% 982.99% 2,562.26% 0.00% 20,010.92% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 2,380.48% 517.40% 1,171.53% 2,945.11% 0.00% 24,356.47% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -77 -58 -75 -109 -123 -180 -140 -155 -175 -222
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -75 -58 -76 -112 -126 -187 -152 -163 -182 -228
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.54 3.09 2.11 0.00 3.61 1.72 2.05 3.96 4.84 3.25
Price to Tangible Book Value (P/TBV)		 2.85 3.46 2.28 0.00 3.95 1.79 2.14 4.14 5.07 3.35
Price to Revenue (P/Rev)		 55.70 59.78 58.90 101.62 122.69 271.36 773.38 8,629.54 10,209.19 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 40.69 36.53 49.22 0.00 91.03 0.00 83.36 171.06 358.18 0.00
Enterprise Value to Revenue (EV/Rev)		 34.60 41.55 31.57 0.00 89.67 111.34 400.29 6,485.71 8,120.94 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.96 -0.95 -0.96 0.00 -0.97 -0.99 -0.98 -0.98 -0.98 -1.01
Leverage Ratio		 1.18 1.20 1.19 0.00 1.19 1.14 1.12 1.12 1.14 1.13
Compound Leverage Factor		 1.14 1.11 1.07 0.00 1.09 1.02 0.93 0.96 1.02 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 6.69 9.50 7.84 0.00 11.48 7.96 11.45 19.92 22.55 14.84
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 9.21 10.65 11.81 0.00 9.64 13.06 18.45 15.42 14.24 14.20
Quick Ratio		 9.01 10.48 11.68 0.00 9.51 12.89 18.18 15.10 13.98 13.97
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -50 -55 -42 -39 -84 -59 -99 -138 -116 -154
Operating Cash Flow to CapEx		 -1,467.72% -2,148.40% -3,548.98% -5,998.30% -3,964.38% -5,203.41% -5,069.78% -5,342.52% -3,705.09% -11,316.69%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.04 0.05 0.04 0.00 0.03 0.01 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 5.03 6.67 8.43 0.00 9.38 3.91 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.19 2.34 2.03 0.00 1.28 0.56 0.21 0.03 0.03 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 72.61 54.69 43.29 0.00 38.89 93.41 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 72.61 54.69 43.29 0.00 38.89 93.41 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 26 40 21 0.00 24 -27 22 28 17 -24
Invested Capital Turnover		 1.11 1.08 1.24 0.00 0.97 1.72 0.21 0.05 0.04 0.00
Increase / (Decrease) in Invested Capital		 -3.14 15 -11 -37 -2.14 -67 0.58 28 -7.44 2.67
Enterprise Value (EV)		 1,074 1,470 1,051 0.00 2,209 1,289 1,828 4,812 6,026 5,069
Market Capitalization		 1,729 2,115 1,960 2,844 3,022 3,142 3,531 6,403 7,575 7,358
Book Value per Share		 $7.77 $7.72 $10.29 $0.00 $7.67 $16.67 $10.47 $9.81 $9.38 $13.47
Tangible Book Value per Share		 $6.93 $6.89 $9.48 $0.00 $7.01 $16.01 $10.04 $9.38 $8.95 $13.04
Total Capital		 681 685 931 0.00 837 1,826 1,725 1,619 1,566 2,265
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -655 -645 -909 0.00 -813 -1,853 -1,704 -1,591 -1,549 -2,289
Capital Expenditures (CapEx)		 3.53 2.88 1.76 1.12 2.54 2.32 3.17 2.40 3.52 1.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -53 -47 -65 0.00 -74 -118 -68 -71 -81 -126
Debt-free Net Working Capital (DFNWC)		 602 598 844 0.00 739 1,735 1,635 1,519 1,468 2,164
Net Working Capital (NWC)		 602 598 844 0.00 739 1,735 1,635 1,519 1,468 2,164
Net Nonoperating Expense (NNE)		 20 13 15 22 22 36 17 24 33 43
Net Nonoperating Obligations (NNO)		 -655 -645 -909 0.00 -813 -1,853 -1,704 -1,591 -1,549 -2,289
Total Depreciation and Amortization (D&A)		 1.27 0.01 -1.04 -3.08 -3.00 -7.12 -12 -8.11 -6.72 -5.44
Debt-free, Cash-free Net Working Capital to Revenue		 -171.27% -132.11% -196.69% 0.00% -301.54% -1,014.90% -1,490.60% -9,611.46% -10,944.07% 0.00%
Debt-free Net Working Capital to Revenue		 1,938.41% 1,690.79% 2,536.31% 0.00% 3,000.11% 14,986.44% 35,818.64% 204,770.62% 197,880.86% 0.00%
Net Working Capital to Revenue		 1,938.41% 1,690.79% 2,536.31% 0.00% 3,000.11% 14,986.44% 35,818.64% 204,770.62% 197,880.86% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.87) ($0.57) $0.00 $0.00 ($0.99) ($1.23) ($0.70) ($0.81) ($0.94) ($1.13)
Adjusted Weighted Average Basic Shares Outstanding		 84.69M 80.63M 0.00 0.00 109.23M 113.15M 164.73M 165.14M 166.84M 167.74M
Adjusted Diluted Earnings per Share		 ($0.87) ($0.57) $0.00 $0.00 ($0.99) ($1.23) ($0.70) ($0.81) ($0.94) ($1.13)
Adjusted Weighted Average Diluted Shares Outstanding		 84.69M 80.63M 0.00 0.00 109.23M 113.15M 164.73M 165.14M 166.84M 167.74M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 88.79M 90.49M 0.00 0.00 109.56M 164.69M 164.99M 167.04M 168.22M 185.91M
Normalized Net Operating Profit after Tax (NOPAT)		 -54 -40 -53 -76 -86 -126 -99 -110 -123 -151
Normalized NOPAT Margin		 -1,596.34% -292.18% -750.07% -1,991.58% 0.00% -16,979.53% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -2,193.86% -384.68% -970.89% -2,570.55% 0.00% -21,724.26% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Revolution Medicines' Financials

When does Revolution Medicines's fiscal year end?

According to the most recent income statement we have on file, Revolution Medicines' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Revolution Medicines' net income changed over the last 6 years?

Revolution Medicines' net income appears to be on an upward trend, with a most recent value of -$600.09 million in 2024, rising from -$41.79 million in 2018. The previous period was -$436.37 million in 2023. View Revolution Medicines' forecast to see where analysts expect Revolution Medicines to go next.

What is Revolution Medicines's operating income?
Revolution Medicines's total operating income in 2024 was -$689.52 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $689.52 million
How has Revolution Medicines revenue changed over the last 6 years?

Over the last 6 years, Revolution Medicines' total revenue changed from $20.17 million in 2018 to $0.00 in 2024, a change of -100.0%.

How much debt does Revolution Medicines have?

Revolution Medicines' total liabilities were at $293.10 million at the end of 2024, a 24.5% increase from 2023, and a 331.1% increase since 2019.

How much cash does Revolution Medicines have?

In the past 5 years, Revolution Medicines' cash and equivalents has ranged from $16.66 million in 2019 to $696.15 million in 2023, and is currently $543.06 million as of their latest financial filing in 2024.

How has Revolution Medicines' book value per share changed over the last 6 years?

Over the last 6 years, Revolution Medicines' book value per share changed from 0.00 in 2018 to 13.47 in 2024, a change of 1,346.6%.


Related Companies

This page (NASDAQ:RVMD) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored
Most traders are panicking. We’re cashing in
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...
Crypto 101 Media | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...
Brownstone Research | Sponsored